The unique region of structural protein VP1 of parvovirus B19 (erythrovirus B19) is important for eliciting neutralizing antibodies that are responsible for eliminating the virus from the peripheral blood and for inducing lifelong immunity. Neutralizing human MAbs bind a conformationally defined epitope spanning VP1 residues 30-42. The DNA sequence encoding the VP1-unique region was determined in parvovirus B19 isolated from peripheral blood and amniotic fluid of nine acutely infected pregnant women, five arthritis patients and two chronically infected children. The amino acid sequences of the VP1-unique region exhibited higher variability in comparison with other B19-specific proteins. To analyse the influence of amino acid variations on antibody binding and protein conformation, two variants of the VP1-unique region were selected and expressed in E. coli as intein-fusion proteins. The selected variants displayed a number of amino acid exchanges in the VP1-unique region and had mutations in the determined epitope and adjacent regions. After purification via affinity chromatography, the dissociation constants K D of VP1-specific human MAbs interacting with the variant antigens and a viral prototype of the VP1-unique region were determined with a quartz crystal microbalance biosensor. A value of 5n4i10 N8 M was determined for the prototype isolate pJB ; the affinity constants for the variant VP1-unique regions were similar. Comparable values were obtained for interaction of antibodies with non-infectious VP1/VP2 capsids produced by recombinant baculovirus and with B19 virions from amniotic fluid. It is concluded that the conformation of the epitope is unaffected by mutations or the environment of the VP1-unique region in virus capsids.
Introduction
Until now, parvovirus B19 is the only member of the Parvoviridae known to cause disease in humans. It was discovered in 1975 by Cossart et al. (1975) and was associated with the common childhood disease erythema infectiosum or fifth disease some years later (Anderson et al., 1983) . Furthermore, acute and chronic polyarthralgia (Naides et al., 1990 ; Reid et al., 1985) and arthritis (Ueno et al., 1993) are frequently associated with parvovirus B19 infections, particularly in adult women. Depending on the patient's haematological and immunological status, B19 infections can provoke Author for correspondence : Susanne Modrow.
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The sequence data presented in this paper have been deposited under the GenBank accession numbers AF293862-AF293881. a variety of additional, more severe clinical symptoms : frequent complications occur in patients with underlying haemolytic disorders, which show a high tendency to develop aplastic crises (Serjeant et al., 1993) . Establishment of persistent parvovirus B19 infections has been reported in patients both with and without underlying immunodeficiencies (Pont et al., 1992 ; Anderson et al., 1985 ; Kurtzman et al., 1987) . Persistence is thought to be due to a qualitatively or quantitatively inadequate humoral immune response (Foto et al., 1993 ; . In particular, the response directed to the VP1-specific parts of the structural proteins seems to be absent in these cases (Kurtzman et al., 1989 a, b) . The pathogenic mechanisms underlying leukopenias and arthritis are not known. Since replication of B19 virus is strongly restricted to the erythroid progenitor cells in the bone marrow, it is not clear how the virus causes destruction of other cells. Further complications of acute infection may occur in pregnant S. Dorsch and others S. Dorsch and others women, since the virus may be transmitted to the foetus and infection in utero can cause hydrops foetalis and foetal death (Brown et al., 1984) .
Soon after infection, antibodies appear directed against the structural proteins VP1 and VP2, which both contain neutralizing epitopes (Sato et al., 1991 a, b ; Yoshimoto et al., 1991) . These two proteins are encoded in the same reading frame located in the 5h-half of the viral single-stranded DNA genome . VP1 and VP2 are identical except for an additional 227 amino acids at the amino terminus of the VP1 protein, the so-called VP1-unique region Cotmore et al., 1986) . A study using empty capsids produced by recombinant baculovirus indicated that only VP1\VP2 capsids are able to create an efficient immune response, due to the neutralizing epitopes present in both the VP1-unique region and the VP2 proteins (Brown et al., 1991 ; Bansal et al., 1993 ; Rosenfeld et al., 1994) .
After the onset of neutralizing antibody production, the virus is cleared rapidly from the circulation in the peripheral blood. Viraemia may be controlled by the application of immunoglobulin preparations containing neutralizing antibodies against parvovirus B19 (van Elsacker-Niele & Kroes, 1999). We have described previously the generation of human MAbs directed against the VP1-unique region that have the capacity to neutralize parvovirus B19 in vitro (Gigler et al., 1999) . In order to investigate whether these antibodies have broad reactivity with various naturally occurring B19 isolates, and may therefore be of therapeutic use, we analysed the influence of amino acid variations in the VP1-unique region on antibody binding and affinity. Virus isolates from patients with various B19-correlated disease manifestations were sequenced. Amino acid variations that would potentially influence the epitope, either directly or indirectly by tertiary effects, were introduced in a vector system expressing a VP1-unique region-intein fusion protein in E. coli. The affinity of interaction with MAbs was then determined with a quartz crystal microbalance (QCM) biosensor.
Methods
Sera. Serum samples from pregnant women containing parvovirus B19 were provided by Dr Frank Louwen at the Westfa$ lische WilhemsUniversita$ t Mu $ nster, Klinik und Poliklinik fu$ r Geburtshilfe und Frauenheilkunde. Samples from arthritis patients were provided by Dr Kristina Broliden, Department for Clinical Virology, Huddinge University Hospital, Stockholm, Sweden. One serum of a chronically infected patient was obtained from Dr Laurids Christiansen, University of Copenhagen, Denmark (Hasle et al., 1994 ; Johansen et al., 1998) and one from Dr Eiffert, Institut fu$ r Medizinische Mikrobiologie, Universita$ t Go$ ttingen, Germany.
Antisera and human MAbs. For generation of polyclonal antisera directed against the VP1-unique region, rabbits were immunized with His-tagged protein that had been expressed in E. coli and purified by Ni# + -affinity chromatography and preparative gel electrophoresis. All sera reacted specifically in ELISA and Western blot assays (data not shown).
Cell lines secreting human MAbs against the VP1-unique region and VP2 virus-like particles were established as described previously (Gigler et al., 1999) and the antibodies were purified from supernatants by protein Gaffinity chromatography.
Amplification of the part of the genome encoding the VP1-unique region by nested PCR. Routine tests for the presence of parvovirus B19 DNA were done by nested PCR for amplification of the VP1\VP2-encoding region with primers that have been published previously (Hemauer et al., 1996) (first round : forward nt 2901-2918, reverse nt 3511-3895 ; second round : forward nt 2956-2972, reverse nt 3431-3448).
An additional PCR was established to amplify in total the genomic region encoding the VP1-unique region, using the following primer pairs. First round : forward nt 2271-2288, reverse nt 3319-3337 ; second round : forward nt 2327-2347, reverse nt 3263-3281. Primer sequences were designed from the published B19 genome sequence (Shade et al., 1986) and synthesized by Metabion (Munich, Germany).
Serum samples were diluted 1 : 1 with water and incubated at 95 mC for 10 min. Aggregated proteins were removed by centrifugation. Two µl aliquots of the supernatants were used in the first cycling reaction. In the second round, 2 µl of the first amplification reaction was applied. The PCR parameters were : 1 min at 95 mC (denaturation), 45 s at 94 mC (hybridization) and 90 s at 72 mC (polymerization). Forty PCR cycles were performed. Identical conditions were used for the first and second rounds of amplification. Ten µl aliquots of each reaction were analysed on a 2 % agarose gel and stained with ethidium bromide. Bands with sizes of approximately 500 bp for the VP1\VP2-encoding region and 950 bp for the VP1-unique region indicated positive results.
DNA sequence analysis. Nested PCR fragments of the VP1-unique region were purified via QIAquick spin columns (Qiagen). Nucleotide sequences were obtained with a 373A Sequencer (Applied Biosystems) by the cycle sequencing method using primers derived from nt 2447-2466 (forward) and 3105-3124 (reverse). The nucleotide sequence data from this study have been deposited in the GenBank database under accession numbers AF293862-AF293881.
Construction of plasmids, expression and purification of the VP1-unique region. The amplified DNA fragments VP1N, for the chosen standard pJB (Shade et al., 1986) , VP1N-1, encoding an exchange of 28E to D, and VPN-2, with exchanges 17K to R, 18A to D, 39Q to H and 43D to H, were cloned into the T7 expression vector pET21aIint, kindly provided by Uli Schmidt (Institut fu$ r Biotechnologie, University of Halle-Wittenberg, Germany). The correct integration of the fragments into the vector was confirmed by sequence analysis. The constructs were introduced into the E. coli strain BL21 (DE3). Bacteria were incubated in LB medium containing 100 µg\ml ampicillin at 37 mC. Expression of the recombinant protein was induced by addition of 1 mM IPTG for at least 3 h of culture. The bacteria were harvested by centrifugation and resuspended in 30 ml of 20 mM HEPES-NaOH, 1 mM EDTA, 100 mM NaCl, pH 8n5. Protein expression was checked by SDS-PAGE followed by silver staining or by Western blot analysis using the polyclonal rabbit serum directed against the VP1-unique region. Bacteria were lysed by the use of a French press and the debris was pelleted at 10 000 g. The supernatant was loaded on a chitin column (NEB) using an FPLC system (Pharmacia Biosystems). The column was washed with 2 vols of 20 mM HEPES-NaOH, 1 mM EDTA, 100 mM NaCl, pH 8n5, 8 vols of 20 mM HEPES-NaOH, 1 mM EDTA, 2 mM NaCl, pH 8n5 and 2 vols of 20 mM HEPES-NaOH, 1 mM EDTA, 100 mM NaCl, pH 8n5. The protein was eluted with 3 vols of 50 mM DTT in a buffer containing 20 mM HEPES-NaOH, 1 mM EDTA, 100 mM NaCl, pH 8n5. Fractions were tested for recombinant proteins by SDS-PAGE and silver staining.
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Parvovirus B19 VP1-unique region Parvovirus B19 VP1-unique region Positive fractions were pooled and concentrated by using a Centriplus concentrator (3 kDa exclusion limit ; Amicon). The protein concentration was determined after dialysis against PBS (0n9 mM KH # PO % , 8n0 mM Na # HPO % , 2n7 mM KCl, 137 mM NaCl) using a Bradford assay (Bio-Rad Laboratories).
Non-infectious VP2 capsids and VP1\VP2 capsids were kindly provided by Ba$ rbel Kaufmann (University of Potsdam, Germany). Expression was performed in a bac-to-bac baculovirus system (Gibco) with a pFast Bac DUAL vector. The capsids were purified by caesium chloride gradient centrifugation.
Western blot assays. For Western blot analysis, purified proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane as described previously (Towbin et al., 1979) . Protein-free regions were blocked with 5 % low-fat dried milk in Tris-buffered saline (pH 7n5) and incubated overnight at room temperature with MAbs or rabbit antiserum diluted 1 : 500 in PBS. Secondary antibodies diluted 1 : 2000 in PBS were added after washing. For the detection of rabbit IgG, alkaline phosphate-conjugated swine antibodies against rabbit immunoglobulins were used (Bio-Rad). For the detection of human IgG, an alkaline phosphate-conjugated goat anti-human antibody was used (Sigma-Aldrich).
Determination of antibody affinity. Determination of the affinities of antibodies reacting with purified proteins representing the various VP1-unique regions, non-infectious VP1\VP2 and VP2 particles and infectious parvovirus B19 was performed on an AFFco 2000. This immunosensor, supplied by the Fraunhofer Institute of Microelectronic Circuits and Systems, Munich, Germany (Ko$ ßlinger et al., 1992) , is based on a quartz crystal microbalance with flow-injection analysis system and peristaltic pump and 20 MHz quartz crystals with gold electrodes. For activation, the gold electrodes were incubated with dithiobissuccinimidyl propionate at a concentration of 0n4 % in DMSO at room temperature for 20 min and washed with PBS, pH 7n4. Subsequently, 10 µl protein A (1 mg\ml) or 10 µl antigen (0n5 mg\ml) was added to the quartz crystals and incubated at 4 mC for 12 h. This immobilization method produces a stable protein layer (Uttenthaler et al., 1998) . After rinsing with PBS and insertion of the quartz crystal into the clip holder, the protein variants were pipetted into the flow system via a 100 µl syringe at concentrations of 1 µM and the kinetics were visualized directly. BSA (0n025 % in PBS) was used as a blocking reagent to prevent unspecific binding. The curves were fitted by using the program Origin version 5.0 (Microcal Software Inc.).
Results

Sequences of virus isolates from B19-infected pregnant women
In order to analyse the genomic variability in the region encoding the VP1-unique region of parvovirus B19, we determined the sequences of parvovirus B19 isolates from nine pregnant women acutely infected with parvovirus B19 (patients A-I), five arthritis patients (patients 2I980728, 6I960625, 8I980219, 2I980414 and 7I980326) and two chronically infected children (patients J and 5940). Two pregnant women had acute B19 infections without symptoms (A and B). Three patients developed exanthema and fatigue (C-E). Four isolates were derived from patients who developed hydrops foetalis or hydroencephalitis of the foetus (F-I). In six cases, virus sequences could be amplified from the amniotic fluid or the foetal serum (B, D, E, F, H and I) ; in three cases, virus was also present in the maternal serum (E, G, H). In four of the patients (B, D, F and I), viral DNA could not be detected in the serum by PCR, even though they had a positive IgG response against structural proteins. The amniotic fluid, however, proved to be positive. In two of these cases (F and I), the foetuses developed hydrops foetalis or foetal hydroencephalitis, respectively.
The nucleotide sequences encoding the VP1-unique region and the adjoining region encoding the amino terminus of the VP2 protein (nt 2444-3194 ; Shade et al., 1986) were determined from all virus isolates. The corresponding amino acid sequences and the standard isolate sequences AU and pJB were compared with those of a consensus sequence derived from all sequences ( Table 1 ). The variability ranged from 0 % (isolates B, E, 2I980414 and 7I980326) and 0n4 % (one amino acid exchange ; isolates A, C, D, I, 2I980728, 6I960625, 8I980219, AU and pJB) to 0n8 % (two amino acid exchanges ; isolates F and H) and 2 % (five amino acid exchanges ; isolates G and J). Sequences obtained from a child with chronic B19 infection displayed a distinctly higher degree of variability (3n2 % or eight amino acid exchanges ; isolate 5940) (Hasle et al., 1994) . Comparison of the virus sequences isolated from maternal sera with those obtained by analysing the corresponding amniotic fluids or ascites did not reveal any variation in protein sequence except for isolate I, with one mutation in isolates I-FO (foetal serum) and I-AS (ascites). As the mutation observed in isolate I was detected in foetal serum and ascites samples, but not in the isolate from amniotic fluid, it probably occurred after infection of the foetus. Amino acid exchanges that could be associated with the transmission of the virus to the amniotic fluid or the development of hydrops foetalis were not observed.
In the regions of the VP1-unique region spanning amino acids 28-136 and 189-247, the number of amino acid exchanges was distinctly elevated. Conservative exchanges were observed predominantly, residues 12D to N, 17K to R, 28E to N, 28E to D, 30V to L, 43D to N, 107N to D, 123V to L, 136E to Q and 189Q to E. Occasionally, additional nonconservative exchanges could be observed : 4E to K, 18A to D, 39 and 120Q to H, 71 and 224K to Q, 84H to Y, 98S to N, 101A to P and 247P to S. The majority of non-conservative exchanges were observed from an isolate obtained from a patient chronically infected with parvovirus B19 (isolate 5940). This may indicate that prolonged viraemia may be associated with an elevated degree of amino acid variation.
Expression of recombinant proteins in E. coli
In order to analyse the influence of naturally occurring amino acid variations on the protein conformation, the aminoterminal 227 residues representing the VP1-unique region of the prototype B19 isolate pJB (VP1N-pJB) were produced in E. coli using the impact T7 system (NEB), which allows protein BJD Table 1 . Amino acid exchanges in the VP1-unique region of parvovirus B19
All amino acid sequences were compared with a hypothetical consensus derived from an optimal sequence with the least variability. Nucleotide exchanges and the corresponding amino acid exchanges are shown. S, Maternal serum ; AF, amniotic fluid ; FO, foetal serum ; AS, ascites. Nucleotide numbering is according to Shade et al. (1986) . Sequences are indicated as : 1, AU ; 2, pJB ; 3, A-S ; 4, C-S ; 5, D-AF ; 6, F-AF ; 7, G-S ; 8, G-FO ; 9, H-S ; 10, H-AF ; 11, I-FO ; 12, I-AS ; 13, J-S ; 14, 5940-S ; 15, 2I980728 ; 16, 6I960625 ; and 17, 8I980219. The following sequences showed no amino acid changes : B-AF, E-S, E-AF, I-AF, 2I980414 and 7I980326. -, No change compared with consensus.
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Observed nucleotide change Amino acid position residue 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 change production and purification under native conditions. The sequences encoding the VP1-unique region were amplified by PCR, fused to a heterologous construct consisting of the region encoding a modified vacuolar membrane ATPase subunit I (VMA-I)-intein (Saccharomyces cerevisiae) and a chitinbinding domain (CBD ; Bacillus circulans) and introduced into the vector pET21aIint. After induction with 1 mM IPTG, the fusion protein consisting of the VP1-unique region, intein and CBD, with a molecular mass of approximately 85 kDa, was produced and positive clones were identified by Western blot analysis using a polyclonal rabbit serum and human MAbs directed against the VP1-unique region (Fig. 1) . Purification of the protein was performed by chitin-affinity chromatography. Addition of DTT as reducing agent resulted in the cleavage of the amino-terminal part, representing the VP1-unique region, from the intein domain. The VP1-unique region could be eluted with the intein-CBP part still bound to the chitinmodified Sepharose and cleared of residual DTT by dialysis. Several variants of the VP1-unique region from patients with different disease manifestations were selected, cloned in the vector pET21aIint and expressed in E. coli. All expressed protein domains (from patients 2I980728, G-S, H-S, 5940-S and pJB ; Table 1) reacted before purification in a Western blot with human MAbs and with rabbit serum directed against the VP1-unique region (data not shown). Of these, two variants of the VP1-unique region, VP1N-1 (isolate G ; 28E to D) and VP1N-2 (isolate 5940 ; 17K to R, 18A to D, 28E to N, 39Q to H and 43D to N), were selected that had large numbers of amino acid variations (five and eight amino acid exchanges) and that displayed significant variations in the amino-terminal part (Fig. 2) . This region is known to contain the epitope that interacts with VP1-specific neutralizing human MAbs. Cell lines secreting these immunoglobulins had been established previously and the antibodies were characterized as IgG1 (Gigler et al., 1999) . Using limited proteolysis of antigenantibody complexes and mass spectroscopy, the region spanning residues 30-42 could be identified as the epitope that is recognized by the MAbs [M. Kohlmann and M. Przybylski blots, the purified VP1-unique regions VP1N-1 and VP1N-2 and the prototype region VP1N-pJB displayed identical reactivities with both the VP1-specific rabbit serum and the human MAbs (Fig. 1 c) .
Determination of antibody affinity
In order to analyse whether the amino acid variations led to differences in protein conformation that resulted in different affinities of the MAbs, a QCM biosensor was applied. The QCM is based on piezoelectric crystals (Sauerbrey, 1959) and can be used to quantify specific antibody-antigen interactions. The frequency obtained as the output signal can be recorded directly and determined with high resolution in a flowinjection analysis system. Frequency shifts and binding kinetics can be evaluated immediately without influences from the viscosity. To calibrate the dissociation constant, the k off and k on rates have to be determined from the binding curves (Fig.  3 ). The dissociation constant is then determined by the formula
All experiments were performed with VP1-specific human MAbs secreted by the human-mouse heteromyeloma cell lines 1418D(1) and 1418D(16). The variable regions of both antibodies have been shown to be identical except for one amino acid exchange in the light κ chain that did not influence epitope recognition (Gigler et al., 1999) . The antibodies were coupled to the surface of quartz crystals that had been coated with protein A to provide optimal access for antigen interaction. Free binding sites were saturated by blocking with BSA. Incubation with PBS as control did not alter the frequency of the crystal. The sample containing purified VP1N-pJB was injected into the flow system. Binding of the protein resulted in a change in the mass of the crystal, which was reflected by a frequency shift of k150 Hz (Fig. 3 a) . The dissociation VP1N gives the actual kinetics. The k on and k off rates are fitted in this graph, as shown. The dissociation constant is then calculated from the formula
constant of MAbs binding to the VP1-unique region of standard isolate pJB was determined as 5n4i10 −) M (Fig. 3 b) , a value that is known to be typical for antigen-antibody interactions. The determined k on and k off rates were 8696 M −" s −" and 0n00047 s −" . Testing the variant VP1-unique regions VP1N-1 and VP1N-2 revealed only slight differences in frequency shifts compared with the standard VP1N-pJB (k180 Hz for VP1N-1, k110 Hz for VP1N-2 in comparison with VP1N-pJB, k150 Hz). The deduced k on rates (9587 and 7875 M −" s −" ) and k off rates (0n00041 and 0n0004 s −" ) are in the same ranges as those observed for VP1N-pJB. The corresponding dissociation constants result in similar values : 4n1i10 −) M for VP1N-1 and 5n2i10 −) M for VP1N-2. As control antigen, virus-like VP2 capsids lacking the VP1-unique region were used, which were produced via recombinant baculovirus and purified by caesium chloride gradient centrifugation. No specific binding to the VP1-specific antibodies immobilized on the crystal surface was observed. Binding of the VP2 capsids could, however, be shown by coating the crystals with VP2-specific human MAbs (data not shown). Application of polyclonal VP1-specific rabbit serum samples resulted in a K D of 1n7i10 −( M, indicating a clearly lower affinity in comparison with the human MAbs. In addition, concentrations of 10 µM (rather than 1 µM) were necessary to obtain a signal, with a distinctly smaller frequency shift of about k10 Hz.
In further experiments, the human MAbs were tested for their capacity to interact with virus-like capsids consisting of VP1 and VP2 proteins produced via recombinant baculovirus and with native B19 virions isolated from the amniotic fluids of B19-infected pregnant women. The corresponding dissociation constants were 7n3i10 −) and 7n5i10 −) M, respectively, indicating a slightly lower, but similar affinity to that obtained for the MAbs interacting with the purified versions of the VP1-unique region (K D l 5n4i10 −) M). As a control, we used samples of amniotic fluids that were determined as PCRnegative and did not contain parvovirus particles. Interaction with human MAbs bound to the crystal surface could not be observed (data not shown).
Combining these data, neither naturally occurring amino acid variations nor the structural environment of the VP1-unique region as part of the VP1 protein in virus-like particles or B19 virions influenced antibody binding or affinity, suggesting that the epitope is surface exposed and highly stable.
Discussion
In our study, we tried to characterize the genomic variability and the antigenic stability of the VP1-unique region of parvovirus B19. Until now, neither the structure nor the function of the VP1-unique region was known. The protein domain is thought to be exposed on the surface of the icosahedral capsid (Rosenfeld et al., 1992) and has an important role in eliciting a proper immune response (Bansal et al., 1993 ; Rosenfeld et al., 1994) . As the VP1-unique region itself contains several neutralizing epitopes, it may be supposed that this protein domain is involved in receptor binding and virus uptake. This hypothesis is encouraged by previous experiments with minute virus of mice, which showed that VP2 capsids containing the virus genome are not infectious (Willwand & Hirt, 1993) . This indicates that the VP1-unique region is necessary for either cell specificity, virus uptake or the uncoating process. Minute virus of mice has a genomic homology of about 50 % to parvovirus B19 and many parallels have been observed in virus replication and promoter transactivation (Shade et al., 1986) .
Recently, we published the establishment of two human MAbs directed against the VP1-unique region of parvovirus B19 (Gigler et al., 1999) . These antibodies are identical except for one amino acid in the variable region of the light κ chain. Both antibodies are highly neutralizing, as shown in assays with human bone marrow cells. In order to analyse the specificity and affinity of the antibodies further, the VP1-unique region of the standard isolate pJB was expressed as an intein-fusion protein and purified via affinity chromatography. By using a QCM biosensor, antibody-antigen interactions can be visualized at very low concentrations. Additionally, this system allows the detection of minor differences, since the dissociation constants can be calculated directly from the k on and k off rates. Both MAbs interacted with the standard isolate VP1N-pJB with a similar affinity, indicated by a K D of 5n4i10 −) M, showing that the amino acid alteration in the κ chain did not influence the interaction with the epitope. This value is in the range of high-affinity antibody interactions as described for other neutralizing immunoglobulins (Stryer, 1991) .
In order to analyse differences in binding of the MAbs to naturally occurring variants of the VP1-unique region, we sequenced a series of different B19 isolates from acutely infected pregnant women, arthritis patients and chronically infected patients and compared the amino acid sequences. Sample 5940 was derived from a chronically infected child with an underlying hyper-IgM immunodeficiency (Hasle et al., 1994) . As shown in previous publications, the variability of the VP1-unique region ranged from 0 to 8n2 % at the amino acid level (Hemauer et al., 1996) . With respect to the reading frame of the structural protein, the variability ranged from 0 to 1n7% at the amino acid level (Erdman et al., 1996) . The highest variabilities were found in isolates derived from patients with persistent infections and patients with transient aplastic crisis. This is in accordance with the results shown by Hokynar et al. (2000) . They described variability at the amino acid level of the VP1-unique region ranging from 1n2 (three amino acids) to 2n8 % (seven amino acids). In our study, the variability of the VP1-specific region was found to range between 0 and 3n2% (eight amino acids). No relationship between specific amino acid exchanges and particular disease manifestations, e.g. hydrops foetalis, or transmission of the virus to the foetus could be observed. By comparing isolates from maternal sera with those from the foetus or the amniotic fluid, it could be shown that transmission of the virus was not associated with mutations or variations.
As the next step, we analysed whether the observed amino acid alterations were associated with changes in the structure of the VP1-unique region. As the epitope recognized by the VP1-specific MAb has been mapped to residues 30-42 (M. Kohlmann, S. Dorsch, S. Modrow and M. Przybylski, unpublished results), we selected two representative protein variants with mutations in and around this area : one was derived from an isolate associated with hydrops foetalis (patient G, VP1N-1 ; exchange of 28E to D) and the second isolate was from a chronically infected child (Hasle et al., 1994) (patient 5940, VP1N-2 ; exchanges of 17K to R, 18A to D, 28E to N, 39Q to H and 43D to H) . By comparing the sequences of the epitope region of the VP1-unique region with those Graphs of the kinetics of the human MAbs with the protein variants VP1N-pJB, VP1N-1 and VP1N-2 are shown. Experimental conditions are described in Fig. 3 . The dissociation constants were 4n1i10 − 8 , 5n4i10 − 8 and 5n2i10 − 8 M, respectively.
published previously, this region was found to be highly conserved. Therefore, the selected naturally existing variants are good representatives to test the affinities of the human MAbs and to correlate these with potential changes in the conformation of the VP1-unique region. On testing the variant proteins with the microbalance biosensor, no differences were observed in the calculated dissociation constants (Fig. 4) . Even though the amino acid variations were in the neighbourhood of or within the determined epitope, the affinities of the human MAbs were identical. Obviously, the variations do not affect the structural conformation of this region, indicating that the epitope must be easy accessible and lying on the surface of the protein and not packed in a tight globular structure. This leads to the suggestion that the amino-terminal part from amino acid 1 to 80 could be folded in a loop-like structure. Variations of individual amino acid residues apparently have no effect on antibody binding ; the conformation of the epitope is still presented in the correct form. Furthermore, the affinity of the human MAbs did not change when VP1\VP2 capsids and native virions from amniotic fluid were used as antigen. This confirms the hypothesis that the epitope is not only presented on the surface of the unique region but also on the capsid surface. The broad reactivity of the VP1-specific MAbs renders them optimal reagents to be applied in immunotherapeutic approaches for the treatment of severe or persistent B19 infections. Our data, however, also indicate that the VP1-unique region is an important component for future vaccines.
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